Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
This is to inform you that Hon'ble National Company Law Appellate Tribunal ('NCLAT'), New Delhi, has passed an order dated 25th April 2023, inter-alia, upheld the order passed by Hon'ble ....
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding an order passed by the National Company Law Appellate Tribunal (NCLAT) related to ongoing litigation involving the company. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements (LODR) Regulation 30, which mandates disclosure of material events. The document includes an annexure detailing litigation status, court orders, and expected financial impact (not quantifiable). There are no financial statements or detailed financial analysis present, only a legal update and regulatory disclosure. The document is not a full annual or interim report, audit report, earnings release, or any financial supplement. It is a regulatory announcement about litigation developments and court orders, fitting the category of Regulatory Filings (RNS). The document length is moderate (5816 characters), and it is not merely an announcement of a report but a substantive regulatory disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-04-26 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2023-04-25 English
Please find enclosed certificate under Regulation 40 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, issued by Mr. Praveen Dua, Practising Company ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the financial year ended 31st March 2023. It is a compliance certificate from a Practising Company Secretary regarding share transfer records and related activities. The document is short (3372 characters) and primarily serves as a certification letter rather than a full financial or management report. It does not contain financial statements or detailed report content but is a regulatory compliance filing. According to the rules, such officer certifications or attestations should be classified as Regulatory Filings (RNS).
2023-04-20 English
Loss of Share Certificates
Regulatory Filings
2023-04-18 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2023-04-18 English
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby confirm that all activities in relation to share transfer facility .
Regulatory Filings Classification · 95% confidence The document is a compliance certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the financial year ended 31st March 2023. It confirms that share transfer activities are maintained by the company's Registrar and Share Transfer Agent. The document is a formal attestation letter addressed to stock exchanges, signed by company officials. It does not contain financial statements, management discussion, or detailed report data. It is primarily a regulatory compliance certification. According to the Certification Rule, such officer certifications or compliance confirmations should be classified as Regulatory Filings (RNS). The document length is short (1933 characters), and it is not a report itself but a compliance certificate.
2023-04-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.